Online citations, reference lists, and bibliographies.
← Back to Search

Ligand-targeted Liposomal Anticancer Drugs.

P. Sapra, T. Allen
Published 2003 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Antibody or ligand-mediated targeting of liposomal anticancer drugs to antigens expressed selectively or over-expressed on tumor cells is increasingly being recognized as an effective strategy for increasing the therapeutic indices of anticancer drugs. This review summarizes some recent advances in the field of ligand-targeted liposomes (LTLs) for the delivery of anticancer drugs. New approaches used in the design and optimization of LTLs is discussed and the advantages and potential problems associated with their therapeutic applications are described. New technologies are widening the spectrum of ligands available for targeting and are allowing choices to be made regarding affinity, internalization and size. The time is rapidly approaching where we will see translation of anticancer drugs entrapped in LTLs to the clinic.
This paper references
10.1016/0167-4889(88)90184-X
UPTAKE AND PROCESSING OF IMMUNOGLOBULIN-COATED LIPOSOMES BY SUBPOPULATIONS OF RAT-LIVER MACROPHAGES
J.T.P. Derksen (1988)
10.1016/S0169-409X(96)00463-2
Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals
K. Maruyama (1997)
Liposomes: Rational Design
A. Janoff (1998)
10.1016/S0378-5173(99)00002-2
Targetability of novel immunoliposomes prepared by a new antibody conjugation technique.
G. Bendas (1999)
Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
M. Sugano (2000)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
D. E. Lopes de Menezes (1998)
10.1016/0005-2736(94)00235-H
Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro.
R. Lee (1995)
Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro.
O. Medina (2001)
10.1016/S1054-3589(08)60146-5
Immunoliposomes for cancer treatment.
J. Park (1997)
10.1016/S0167-4889(02)00256-2
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.
U. Nielsen (2002)
10.1038/bjc.1996.625
Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
D. Goren (1996)
10.1016/S0163-7827(00)00011-4
Current status of pH-sensitive liposomes in drug delivery.
D. Drummond (2000)
10.1016/S0304-3835(97)00326-1
Anti-HER2 immunoliposomes for targeted therapy of human tumors.
J. Park (1997)
10.1002/(SICI)1097-0215(19990301)80:5<723::AID-IJC16>3.0.CO;2-L
Sterically stabilized anti‐idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B‐cell lymphoma model
Y. Tseng (1999)
10.1023/A:1010960900254
Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo
O. Ishida (2004)
10.1038/sj.bjc.6600423
Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes
C. Marty (2002)
10.1016/S0014-5793(97)00905-8
Immunoliposomes bearing polyethyleneglycol‐coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo
K. Maruyama (1997)
10.1056/NEJMOA011795
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
B. E. C. Oiffier (2002)
10.1016/S1461-5347(00)00280-7
Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries.
Nielsen (2000)
10.3109/10611869909085495
P0 protein mediated targeting of liposomes to melanoma cells with high level of ICAM-1 expression.
M. R. Jaafari (1999)
10.1093/NAR/22.22.4681
Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide.
J. P. Bongartz (1994)
Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
S. M. Nam (1999)
10.1038/256495a0
Continuous cultures of fused cells secreting antibody of predefined specificity
G. Köhler (1975)
10.3109/10428199509056847
Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment.
L. Pilarski (1995)
10.1016/S0005-2736(96)00228-3
pH-induced destabilization of lipid bilayers by a lipopeptide derived from influenza hemagglutinin.
A. Bailey (1997)
10.1248/BPB.23.791
In vivo targeting by liposomes.
K. Maruyama (2000)
10.3109/08982109409037027
Antibody-Mediated Targeting of Long-Circulating (StealthR) Liposomes
T. Allen (1994)
10.1016/0165-6147(94)90314-X
Long-circulating (sterically stabilized) liposomes for targeted drug delivery.
T. Allen (1994)
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
J. Baselga (1998)
Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice.
S. Huang (1992)
Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose.
A. V. van Hof (1996)
10.1038/bjc.1996.484
Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo.
M. Vingerhoeds (1996)
Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors.
N. Boman (1994)
10.1016/0005-2736(91)90385-L
Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target.
A. Klibanov (1991)
Oncotic pressure in solid tumors is elevated.
M. Stohrer (2000)
10.1038/nrc903
Ligand-targeted therapeutics in anticancer therapy
T. Allen (2002)
10.1038/35101072
Improving the efficacy of antibody-based cancer therapies
P. Carter (2001)
10.1016/S0005-2728(01)00165-7
p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups.
V. Torchilin (2001)
10.1016/S0168-3659(01)00460-6
Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein.
H. Matsuo (2001)
10.1007/s00262-002-0266-6
Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors
Y. Lu (2002)
10.1073/PNAS.83.8.2699
Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo.
D. Aragnol (1986)
10.1182/BLOOD.V83.5.1329.BLOODJOURNAL8351329
Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest.
M. A. Ghetie (1994)
10.1002/JPS.2600791107
Characterization of in vivo immunoliposome targeting to pulmonary endothelium.
K. Maruyama (1990)
Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.
P. Sapra (2002)
10.1016/0092-8674(83)90291-X
Endocytosis of liposomes and intracellular fate of encapsulated molecules: Encounter with a low pH compartment after internalization in coated vesicles
R. Straubinger (1983)
10.1016/S0005-2736(97)00056-4
Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.
J. A. Harding (1997)
10.1016/S0022-2836(65)80093-6
Diffusion of univalent ions across the lamellae of swollen phospholipids.
A. Bangham (1965)
10.1016/S0005-2736(01)00409-6
Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells.
T. Ishida (2001)
10.1016/s0889-8588(18)30346-0
Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules.
L. Pilarski (1992)
10.1016/0165-2478(91)90040-H
Immunogenicity of immunoliposomes.
N. Phillips (1991)
10.1016/S0169-409X(02)00042-X
Folate-mediated delivery of macromolecular anticancer therapeutic agents.
Y. Lu (2002)
10.1016/S0169-409X(99)00042-3
Possibility of active targeting to tumor tissues with liposomes.
Maruyama (1999)
Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells.
M. A. Ghetie (1999)
10.3109/08982109709035510
In vivo targeting of surface-modified liposomes to metastatically growing colon carcinoma cells and sinusoidal endothelial cells in the rat liver.
G. Scherphof (1997)
10.1016/S0005-2736(01)00357-1
In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach.
D. Iden (2001)
10.1016/s0021-9258(19)68359-6
Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting.
F. Martín (1982)
10.1002/j.1552-4604.1996.tb04152.x
Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma
D. Northfelt (1996)
The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer.
L. Regimbald (1996)
10.1006/JMBI.2000.4026
Selection of tumor-specific internalizing human antibodies from phage libraries.
M. A. Poul (2000)
10.1182/BLOOD.V89.5.1824
CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements.
A. Szczepek (1997)
10.1023/A:1013085811044
Pharmacokinetics of Differently Designed Immunoliposome Formulations in Rats with Or Without Hepatic Colon Cancer Metastases
G. Koning (2004)
10.1016/0014-5793(87)80506-9
Large unilamellar liposomes with low uptake into the reticuloendothelial system
T. Allen (1987)
10.1042/BST0231073
Immunoliposome-mediated targeting of anti-cancer drugs in vivo.
T. Allen (1995)
Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice.
I. Ahmad (1993)
10.1016/0014-5793(96)00521-2
Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface‐grafted poly(ethylene glycol)
D. Kirpotin (1996)
10.1021/JA952725M
Peptide-Mediated Release of Folate-Targeted Liposome Contents from Endosomal Compartments1
K. Vogel (1996)
10.3109/10428199509064940
Chronic lymphocytic leukemia with an interfollicular architecture: avoiding diagnostic confusion with monocytoid B-cell lymphoma.
D. Nguyen (1995)
Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.
L. Baxter (1994)
10.1073/PNAS.92.5.1327
Development of anti-p185HER2 immunoliposomes for cancer therapy.
J. Park (1995)
10.1016/S0014-5793(99)01320-4
A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs
T. Ishida (1999)
Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.
Sandy Ni (2002)
10.1182/BLOOD.V100.2.594
Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid.
X. Q. Pan (2002)
10.3109/08982109909024786
Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells
D. Menezes (1999)
Vascular endothelial growth factor and vascular targeting of solid tumors.
R. Brekken (2001)
10.1021/BC00022A008
Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes.
S. Zalipsky (1993)
10.1124/MOL.62.4.864
Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study.
Yun-Long Tseng (2002)
10.1081/LPR-100103167
CORRELATIONS BETWEEN THE RATE OF INTRACELLULAR RELEASE OF ENDOCYTOSED LIPOSOMAL DOXORUBICIN AND CYTOTOXICITY AS DETERMINED BY A NEW ASSAY
M. J. Kirchmeier (2001)
10.1038/nrd984
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
O. H. Brekke (2003)
10.1081/LPR-120004771
ADVENTURES IN TARGETING
T. Allen (2002)
pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs.
J. Connor (1986)
10.1016/S0163-7258(99)00018-2
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs.
G. Dubowchik (1999)
10.1080/10611860290007559
By-passing of P-glycoprotein Using Immunoliposomes
J. Huwyler (2002)
10.1002/(SICI)1097-4636(200007)51:1<10::AID-JBM2>3.0.CO;2-R
Targeted drug delivery to C6 glioma by transferrin-coupled liposomes.
D. A. Eavarone (2000)
10.1038/sj.bjc.6690588
Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells
G. Koning (1999)
10.1016/0005-2736(93)90351-Y
Molecular mechanism of the lipid vesicle longevity in vivo.
G. Blume (1993)
Human immune response to multiple injections of murine monoclonal IgG.
D. L. Shawler (1985)
10.1200/JCO.1999.17.1.268
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
M. Czuczman (1999)
10.1016/S0005-2736(01)00411-4
Targeting Stealth liposomes in a murine model of human small cell lung cancer.
J. Moreira (2001)
10.1016/S0168-3659(01)00315-7
Tumor targeting using anti-her2 immunoliposomes.
J. Park (2001)
10.1007/978-3-662-22115-0
Long Circulating Liposomes: Old Drugs, New Therapeutics
M. Woodle (1998)
10.1016/0005-2736(95)00085-H
A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells.
T. Allen (1995)
10.3109/08982100009029385
Receptor-Specific Delivery of Liposomes Via Folate-Peg-Chol
W. Guo (2000)
10.1016/S0005-2736(00)00334-5
Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer.
E. Moase (2001)
10.1073/PNAS.85.18.6949
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.
A. Gabizon (1988)
10.1021/BC9801124
Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies.
A. Gabizon (1999)
10.1016/S0005-2736(99)00091-7
Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.
G. Koning (1999)
10.1016/0005-2736(94)00263-O
Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies.
K. Maruyama (1995)
10.1016/0005-2736(94)90325-5
Novel pH-sensitive liposomes: liposomes bearing a poly(ethylene glycol) derivative with carboxyl groups.
K. Kono (1994)
10.1146/ANNUREV.IY.12.040194.002245
Making antibodies by phage display technology.
G. Winter (1994)
10.1016/S0005-2736(01)00386-8
A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer.
J. Moreira (2001)
10.1016/0169-409X(95)00029-7
Pharmacokinetics of long-circulating liposomes
T. Allen (1995)
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft.
F. Yuan (1994)
10.1016/S0005-2736(01)00368-6
Investigation of the cellular uptake of E-Selectin-targeted immunoliposomes by activated human endothelial cells.
S. Kessner (2001)
10.1016/S0005-2736(00)00203-0
Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo.
D. E. Lopes de Menezes (2000)
Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
F. Pastorino (2003)
10.1016/0005-2736(91)90201-I
Pharmacokinetics of stealth versus conventional liposomes: effect of dose.
T. Allen (1991)
10.1016/S0169-409X(99)00043-5
Immunoliposomes for the targeted delivery of antitumor drugs.
Mastrobattista (1999)
Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.
D. Flavell (1997)
10.1016/0005-2736(95)00138-S
Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures.
C. B. Hansen (1995)
Vascular endothelial growth factor as a marker of tumor endothelium.
R. Brekken (1998)
10.1089/CBR.1997.12.177
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
A. Demidem (1997)
10.1016/S0083-6729(00)60022-5
Liposome targeting to tumors using vitamin and growth factor receptors.
D. Drummond (2000)
10.1016/0005-2736(87)90114-3
Targeting of anti-Thy 1.1 monoclonal antibody conjugated liposomes in Thy 1.1 mice after intravenous administration.
R. Debs (1987)
10.1200/JCO.1998.16.8.2825
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
P. Mclaughlin (1998)
10.1038/sj.onc.1205347
Anti-neovascular therapy using novel peptides homing to angiogenic vessels
N. Oku (2002)
Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.
R. E. Eliaz (2001)
10.1016/S0169-409X(96)00402-4
Therapeutic opportunities for targeted liposomal drug delivery
T. Allen (1996)
10.1016/S0005-2736(99)00234-5
In vitro characterization of a novel polymeric-based pH-sensitive liposome system.
M. Zignani (2000)
10.1016/s0021-9258(17)44020-8
Interactions of immunoliposomes with target cells.
A. Huang (1983)
10.1002/ijc.10242
Intracellular targeting therapy of cisplatin‐encapsulated transferrin‐polyethylene glycol liposome on peritoneal dissemination of gastric cancer
H. Iinuma (2002)
10.1021/BI962148U
Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
D. Kirpotin (1997)
10.1016/S0168-3659(01)00326-1
VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery.
S. Dagar (2001)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
J. Park (2002)
10.1023/A:1008365716693
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
T. Safra (2000)
10.1038/nbt0796-845
High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice
D. Fishwild (1996)
10.1007/BF00047468
Transport of molecules across tumor vasculature
R. Jain (2004)
10.1021/BI00517A043
Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds.
F. Martín (1981)
10.3109/08982109409037057
Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes.
E. Bolotin (1994)
10.1023/A:1014434732752
Use of the Post-Insertion Technique to Insert Peptide Ligands into Pre-Formed Stealth Liposomes with Retention of Binding Activity and Cytotoxicity
J. Moreira (2004)



This paper is referenced by
BORON NEUTRON CAPTURE THERAPY : DELIVERY AGENTS USED IN BORON ADMINISTRATION THERAPEUTICAL PRACTICE
Galeş N. Laurenţia (2016)
10.1007/978-1-4020-6289-6_1
Micro and Nano Systems in Biomedicine and Drug Delivery
N. Hasirci (2007)
10.1517/17425247.2014.866650
Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors
Bilyana M. Dicheva (2014)
10.3109/10611860903353354
PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells
Wenbing Dai (2010)
10.1039/B923535N
Liposomes as ‘smart’ pharmaceutical nanocarriers
R. Sawant (2010)
10.1201/B18654-5
Liposomes as a Drug Delivery System
Kacoli Banerjee (2015)
10.1016/j.addr.2009.11.021
Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.
S. Gunaseelan (2010)
Functional Anchoring Lipids for Drug Delivery Carrier Fabrication and Cell Surface Re-Engineering Applications
Pratima Vabbilisetty (2014)
10.1016/B978-0-12-416039-2.00007-0
Building and characterizing antibody-targeted lipidic nanotherapeutics.
D. Kirpotin (2012)
10.1016/J.JCIS.2006.12.082
Relationship between N,N-dialkyl chitosan monolayer and corresponding vesicle.
M. Li (2007)
10.1021/ar8002442
Lipid-shelled vehicles: engineering for ultrasound molecular imaging and drug delivery.
K. Ferrara (2009)
10.1007/978-981-10-0818-4_7
Cellular Response of Therapeutic Nanoparticles
A. Kumari (2016)
10.1016/B978-0-323-41736-5.00007-8
Chapter 7 – Targeting and imaging of cancer cells using nanomaterials
B. Guler (2016)
10.1134/S1995078008030105
Liposomes as nanocarriers of lipid-conjugated antitumor drugs melphalan and methotrexate
E. Vodovozova (2008)
10.1016/J.BIOPHA.2006.08.005
Influence of oil droplet surface charge on the performance of antibody--emulsion conjugates.
D. Goldstein (2007)
10.1177/030089160809400217
Drug Delivery Systems: Application of Liposomal Anti-Tumor Agents to Neuroectodermal Cancer Treatment
D. Di Paolo (2008)
10.1201/9781420009552.CH14
History of Liposomes
J. B. Cannon (2008)
10.1208/s12248-012-9330-0
Challenges in Development of Targeted Liposomal Therapeutics
R. Sawant (2012)
10.1016/J.EJPB.2007.08.010
Folate-tethered emulsion for the target delivery of retinoids to cancer cells.
S. Kim (2008)
10.1016/j.jare.2018.06.005
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
S. Hossen (2019)
10.5216/REF.V2I2.2019
AVALIAÇÃO DO EFEITO ANTIMICROBIANO IN VITRO DE CEFALOSPORINAS EM LIPOSSOMAS UNILAMELARES
Ieda Maria Sapateiro Torres (2007)
10.1016/j.ijpharm.2009.03.018
Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
Jie Gao (2009)
10.3390/ijms20092156
Optimisation of Folate-Mediated Liposomal Encapsulated Arsenic Trioxide for Treating HPV-Positive Cervical Cancer Cells In Vitro
Anam Akhtar (2019)
10.1039/C3TB20412J
Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells in Vitro and in Vivo.
Hang Xing (2013)
10.1002/adma.201704307
Biodistribution, Clearance, and Long-Term Fate of Clinically Relevant Nanomaterials.
Joël Bourquin (2018)
10.1155/2011/376548
Modeling the Release Kinetics of Poorly Water-Soluble Drug Molecules from Liposomal Nanocarriers
S. Loew (2011)
HER-2 targeted immunonanoparticles for breast cancer chemotherapy
R. Dhankar (2011)
10.1021/acs.bioconjchem.7b00087
A Novel "Prebinding" Strategy Dramatically Enhances Sortase-Mediated Coupling of Proteins to Liposomes.
J. Silvius (2017)
10.2147/IJN.S124770
Targeted multidrug delivery system to overcome chemoresistance in breast cancer
Y. Tang (2017)
10.1007/s10989-011-9245-0
Fluorescence Studies on a Designed Peptide of REIP as a Potential Hydrophobic Drug Carrier
Y. Lu (2011)
10.1155/2013/705265
Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting
F. Perche (2013)
10.1016/j.colsurfb.2018.10.007
Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy.
Abhishesh Kumar Mehata (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar